Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
NCT ID: NCT05162443
Last Updated: 2025-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
APPROVED_FOR_MARKETING
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
NCT06039384
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
NCT04673942
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
NCT03510104
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
NCT01359982
QTX3046 in Patients With KRAS G12D Mutations
NCT06428500
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
adagrasib (MRTX849)
adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed presence of a KRASG12C mutation
* Ineligible for an ongoing clinical trial of MRTX849
* No available or not eligible for standard of care treatment
* Adequate organ function
* CNS Metastases (within set parameters) are allowed
* ECOG performance status of ≤ 2
Exclusion Criteria
* Prior therapy targeting a KRAS G12C mutation
* Other active cancer
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
California Pacific Medical Center
San Francisco, California, United States
Providence Medical Group Santa Rosa - Cancer Center
Santa Rosa, California, United States
Hartford Hospital
Hartford, Connecticut, United States
Piedmont Cancer Institute
Atlanta, Georgia, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Renown Health
Reno, Nevada, United States
Lehigh Valley Cancer Institute
Allentown, Pennsylvania, United States
Lumi Research
Kingwood, Texas, United States
Virginia Cancer Institute
Richmond, Virginia, United States
Seattle Integrative Cancer Center
Renton, Washington, United States
Swedish Cancer Institute
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
EAP Investigator Requests
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
849-EAP-001
Identifier Type: OTHER
Identifier Source: secondary_id
CA239-0067
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.